Shots:

• The company advances P-ll/lll PanCAN Precision Promise study by evaluating nadunolimab in combination with CT vs SOC as 1L experimental therapy in metastatic pancreatic cancer (PDAC)
• The trial utilizes a Bayesian platform and involves the enrolment of 175 patients on each experimental arm. The 1EPs of the study is OS while the results of the study are expected to be available in 2027 or earlier
• The company is planning to submit the pre-IND application to the US FDA in Q2’22. Cantargia will fund the nadunolimab arm and will be responsible for supplying the drug

Ref: Cantargia | Image: Linkedin